Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
NEW YORK--(BUSINESS WIRE)--Nov 27, 2019--
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the following upcoming conferences:
- Evercore ISI 2 nd Annual HealthCONx Conference
- Gaurav Shah, M.D., President and CEO, is scheduled to present on Tuesday, December 3, 2019, at 11:20 a.m. Eastern Time.
- Piper Jaffray’s 31 st Annual Healthcare Conference
- Gaurav Shah, M.D., President and CEO, is scheduled to present on Thursday, December 5, 2019, at 1:00 p.m. Eastern Time.
A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients contending with rare genetic diseases. Rocket’s clinical programs using LVV-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket’s first clinical program using AAV-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rocket’s pre-clinical pipeline program is for Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. For more information about Rocket, please visit www.rocketpharma.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191127005155/en/
CONTACT: Claudine Prowse, Ph.D.
SVP, Strategy & Corporate Development
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
INDUSTRY KEYWORD: HEALTH STEM CELLS GENETICS PHARMACEUTICAL CARDIOLOGY BIOTECHNOLOGY
SOURCE: Rocket Pharmaceuticals, Inc.
Copyright Business Wire 2019.
PUB: 11/27/2019 07:00 AM/DISC: 11/27/2019 07:01 AM